Industries · Drug Discovery & Biotechnology
OMICS4 runs the wet-lab side of your discovery programs (target identification support, mechanism-of-action transcriptomics and translational biomarker sample workflows) via our in-house platforms, bookable end to end.
Overview
OMICS4 supports drug discovery and biotech teams with target identification support, mechanism-of-action transcriptomics, and translational biomarker sample generation, run end-to-end via our in-house platforms, from wet lab to QC-checked dataset.
OMICS4 capabilities
Target prioritization grounded in omics and pathway context.
Dose- and time-resolved transcriptional readouts on compound effect.
Molecular signatures for hit prioritization beyond single endpoints.
Preclinical-to-clinical biomarker bridging for regulatory packages, delivered by GenXMap's Computational Biology & AI layer on top of our wet-lab data.
How OMICS4 adapts
No two programs run the same workflow. Here is how OMICS4 fits into what you already have in place.
Your programs move through discrete stage gates: hit-to-lead, lead optimization, IND-enabling.
Study design and turnaround are scoped per stage gate, so data lands in time for go/no-go decisions.
Compound and target confidentiality is critical, sometimes across CRO/CDMO relationships.
Coded sample IDs and NDA-governed workflows keep target and compound identity compartmentalized.
Internal pipelines and reference resources (proprietary compound libraries, internal signatures) already exist.
Our outputs are formatted to integrate with your existing informatics stack rather than replace it.
Budget and timeline pressure leave no room for exploratory-only deliverables.
Every analysis is scoped against a decision you need to make, not delivered as a generic report.
Have a project in this space?